MetLife Investment Management’s Viridian Therapeutics VRDN Stock Holding History

MetLife Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.9M	Buy	708,527 +664,542	+1,511%	+$19.7M	0.07%	272
2025 Q4	$1.37M	Buy	43,985 +356	+0.8%	+$9.76K	0.01%	1261
2025 Q3	$942K	Hold	43,629	–	–	﹤0.01%	1482
2025 Q2	$610K	Hold	43,629	–	–	﹤0.01%	1590
2025 Q1	$588K	Sell	43,629 -666	-2%	-$11.3K	﹤0.01%	1641
2024 Q4	$849K	Buy	44,295 +7,914	+22%	+$172K	﹤0.01%	1504
2024 Q3	$828K	Hold	36,381	–	–	﹤0.01%	1497
2024 Q2	$473K	Buy	36,381 +10,811	+42%	+$150K	﹤0.01%	1743
2024 Q1	$448K	Buy	25,570 +3,299	+15%	+$64K	﹤0.01%	1736
2023 Q4	$485K	Hold	22,271	–	–	﹤0.01%	1701
2023 Q3	$342K	Hold	22,271	–	–	﹤0.01%	1859
2023 Q2	$530K	Buy	22,271 +2,428	+12%	+$62.3K	﹤0.01%	1660
2023 Q1	$505K	Hold	19,843	–	–	﹤0.01%	1637
2022 Q4	$580K	Buy	19,843 +6,129	+45%	+$141K	﹤0.01%	1545
2022 Q3	$281K	Hold	13,714	–	–	﹤0.01%	2070
2022 Q2	$159K	Buy	+13,714	New	+$184K	﹤0.01%	2458

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MetLife Investment Management's VRDN Position: Q1 2026 in Review

MetLife Investment Management increased its Viridian Therapeutics (VRDN) stake by 1,511% in Q1 2026, buying an estimated $19.7M and bringing the position to 708,527 shares worth $13.9M. The position accounts for 0.07% of the portfolio, ranked #272.

MetLife Investment Management first reported a position in VRDN in Q2 2022 and has held it in 16 quarters since. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

MetLife Investment Management held 708,527 shares of Viridian Therapeutics worth $13.9M as of Q1 2026.
MetLife Investment Management bought 664,542 Viridian Therapeutics shares in Q1 2026, an estimated $19.7M.
Viridian Therapeutics made up 0.07% of MetLife Investment Management's portfolio in Q1 2026, its #272 holding.
MetLife Investment Management first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 16 quarters since.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.